{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:06Z","timestamp":1793119626928,"version":"4.5.0"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,5,27]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dupilumab is approved for the treatment of atopic dermatitis, asthma, and other allergic diseases. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at a higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among patients with asthma receiving dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based cohort study included patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting \u03b2-agonists (LABA), or ICS\/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and secondary outcomes included other malignancies and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 14\u2009936 dupilumab-treated and 734\u2009126 ICS\/LABA-treated patients with asthma were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54\n                      <jats:italic>versus<\/jats:italic>\n                      43 cases, hazard ratio (HR) 1.79, 95% CI 1.19\u20132.71), especially T-cell and natural killer (NK)-cell lymphomas (19\n                      <jats:italic>versus<\/jats:italic>\n                      \u226410 cases, HR 4.58, 95% CI 1.82\u201311.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (328\n                      <jats:italic>versus<\/jats:italic>\n                      793 deaths, HR 0.65, 95% CI 0.57\u20130.74).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.00139-2025","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T10:20:11Z","timestamp":1750328411000},"page":"2500139","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study"],"prefix":"10.1183","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-4144","authenticated-orcid":false,"given":"Kevin Sheng-Kai","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Brumbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-0985","authenticated-orcid":false,"given":"Rebecca R.","family":"Saff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-0473","authenticated-orcid":false,"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-645X","authenticated-orcid":false,"given":"Serena Yun-Chen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Westmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ebriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-7654","authenticated-orcid":false,"suffix":"Jr","given":"Carlos A.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2025092508000766000_66.3.2500139.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1944CI"},{"key":"2025092508000766000_66.3.2500139.2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaip.2017.04.038","article-title":"Biologic therapy and novel molecular targets of severe asthma","volume":"5","author":"Pepper","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025092508000766000_66.3.2500139.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1102LE"},{"key":"2025092508000766000_66.3.2500139.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2025092508000766000_66.3.2500139.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"2025092508000766000_66.3.2500139.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"2025092508000766000_66.3.2500139.7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025092508000766000_66.3.2500139.8","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16388"},{"key":"2025092508000766000_66.3.2500139.9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91 .","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025092508000766000_66.3.2500139.10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/DAD.0000000000001875","article-title":"Evolution of dupilumab-associated cutaneous atypical lymphoid infiltrates","volume":"43","author":"Sokumbi","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"2025092508000766000_66.3.2500139.11","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1111\/all.16265","article-title":"Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study","volume":"79","author":"Tsai","year":"2024","journal-title":"Allergy"},{"key":"2025092508000766000_66.3.2500139.12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","article-title":"Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study","volume":"54","author":"Tsai","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025092508000766000_66.3.2500139.13","first-page":"991","article-title":"Long-term safety of dupilumab in patients with moderate-to-severe asthma: TRAVERSE continuation study","volume":"12","author":"Maspero","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025092508000766000_66.3.2500139.14","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/all.16538","article-title":"Adverse outcomes associated with short\u2010acting beta\u2010agonist overuse in asthma: a systematic review and meta\u2010analysis","volume":"80","author":"Tsao","year":"2025","journal-title":"Allergy"},{"key":"2025092508000766000_66.3.2500139.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567"},{"key":"2025092508000766000_66.3.2500139.16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/02770903.2018.1520865","article-title":"Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials","volume":"56","author":"Zayed","year":"2019","journal-title":"J Asthma"},{"key":"2025092508000766000_66.3.2500139.17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/cid\/ciac745","article-title":"Dupilumab use is associated with protection from coronavirus disease 2019 mortality: a retrospective analysis","volume":"76","author":"Donlan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025092508000766000_66.3.2500139.18","doi-asserted-by":"crossref","first-page":"11871","DOI":"10.1002\/cam4.5875","article-title":"Cancer incidence after asthma diagnosis: evidence from a large clinical research network in the United States","volume":"12","author":"Guo","year":"2023","journal-title":"Cancer Med"},{"key":"2025092508000766000_66.3.2500139.19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.rmed.2012.12.002","article-title":"Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer","volume":"107","author":"Lee","year":"2013","journal-title":"Respir Med"},{"key":"2025092508000766000_66.3.2500139.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3544"},{"key":"2025092508000766000_66.3.2500139.21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1556\/030.62.2015.4.2","article-title":"Interleukin-13 as an important cytokine: a review on its roles in some human diseases","volume":"62","author":"Seyfizadeh","year":"2015","journal-title":"Acta Microbiol Immunol Hung"},{"key":"2025092508000766000_66.3.2500139.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5301"},{"key":"2025092508000766000_66.3.2500139.23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaad.2008.10.010","article-title":"A case of recurrent pseudolymphomatous folliculitis: a mimic of cutaneous lymphoma","volume":"60","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2025092508000766000_66.3.2500139.24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.alit.2020.01.005","article-title":"Implications of IL-13R\u03b12 in atopic skin inflammation","volume":"69","author":"Furue","year":"2020","journal-title":"Allergol Int"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00139-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:00:16Z","timestamp":1758812416000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00139-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1183\/13993003.00139-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00139-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}